470 related articles for article (PubMed ID: 27900261)
1. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome.
Knani I; Earley BJ; Udi S; Nemirovski A; Hadar R; Gammal A; Cinar R; Hirsch HJ; Pollak Y; Gross I; Eldar-Geva T; Reyes-Capo DP; Han JC; Haqq AM; Gross-Tsur V; Wevrick R; Tam J
Mol Metab; 2016 Dec; 5(12):1187-1199. PubMed ID: 27900261
[TBL] [Abstract][Full Text] [Related]
2. Dysfunctional oleoylethanolamide signaling in a mouse model of Prader-Willi syndrome.
Igarashi M; Narayanaswami V; Kimonis V; Galassetti PM; Oveisi F; Jung KM; Piomelli D
Pharmacol Res; 2017 Mar; 117():75-81. PubMed ID: 28007570
[TBL] [Abstract][Full Text] [Related]
3. Progressive postnatal decline in leptin sensitivity of arcuate hypothalamic neurons in the Magel2-null mouse model of Prader-Willi syndrome.
Pravdivyi I; Ballanyi K; Colmers WF; Wevrick R
Hum Mol Genet; 2015 Aug; 24(15):4276-83. PubMed ID: 25926624
[TBL] [Abstract][Full Text] [Related]
4. Peripheral endocannabinoid signaling controls hyperphagia in western diet-induced obesity.
Argueta DA; DiPatrizio NV
Physiol Behav; 2017 Mar; 171():32-39. PubMed ID: 28065722
[TBL] [Abstract][Full Text] [Related]
5. The Prader-Willi syndrome proteins MAGEL2 and necdin regulate leptin receptor cell surface abundance through ubiquitination pathways.
Wijesuriya TM; De Ceuninck L; Masschaele D; Sanderson MR; Carias KV; Tavernier J; Wevrick R
Hum Mol Genet; 2017 Nov; 26(21):4215-4230. PubMed ID: 28973533
[TBL] [Abstract][Full Text] [Related]
6. Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling.
Tam J; Szanda G; Drori A; Liu Z; Cinar R; Kashiwaya Y; Reitman ML; Kunos G
Mol Metab; 2017 Oct; 6(10):1113-1125. PubMed ID: 29031713
[TBL] [Abstract][Full Text] [Related]
7. Chronic diazoxide treatment decreases fat mass and improves endurance capacity in an obese mouse model of Prader-Willi syndrome.
Bischof JM; Wevrick R
Mol Genet Metab; 2018 Apr; 123(4):511-517. PubMed ID: 29506955
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of the mouse Magel2 gene results in growth abnormalities similar to Prader-Willi syndrome.
Bischof JM; Stewart CL; Wevrick R
Hum Mol Genet; 2007 Nov; 16(22):2713-9. PubMed ID: 17728320
[TBL] [Abstract][Full Text] [Related]
9. Muscle dysfunction caused by loss of Magel2 in a mouse model of Prader-Willi and Schaaf-Yang syndromes.
Kamaludin AA; Smolarchuk C; Bischof JM; Eggert R; Greer JJ; Ren J; Lee JJ; Yokota T; Berry FB; Wevrick R
Hum Mol Genet; 2016 Sep; 25(17):3798-3809. PubMed ID: 27436578
[TBL] [Abstract][Full Text] [Related]
10. CB
Drori A; Gammal A; Azar S; Hinden L; Hadar R; Wesley D; Nemirovski A; Szanda G; Salton M; Tirosh B; Tam J
Elife; 2020 Nov; 9():. PubMed ID: 33210603
[TBL] [Abstract][Full Text] [Related]
11. Sleeve gastrectomy leads to weight loss in the Magel2 knockout mouse.
Arble DM; Pressler JW; Sorrell J; Wevrick R; Sandoval DA
Surg Obes Relat Dis; 2016 Dec; 12(10):1795-1802. PubMed ID: 27396546
[TBL] [Abstract][Full Text] [Related]
12. Magel2 Modulates Bone Remodeling and Mass in Prader-Willi Syndrome by Affecting Oleoyl Serine Levels and Activity.
Baraghithy S; Smoum R; Drori A; Hadar R; Gammal A; Hirsch S; Attar-Namdar M; Nemirovski A; Gabet Y; Langer Y; Pollak Y; Schaaf CP; Rech ME; Gross-Tsur V; Bab I; Mechoulam R; Tam J
J Bone Miner Res; 2019 Jan; 34(1):93-105. PubMed ID: 30347474
[TBL] [Abstract][Full Text] [Related]
13. Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist.
Bischof JM; Van Der Ploeg LH; Colmers WF; Wevrick R
Br J Pharmacol; 2016 Sep; 173(17):2614-21. PubMed ID: 27339818
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic potential of targeting the peripheral endocannabinoid/CB
Tam J; Hinden L; Drori A; Udi S; Azar S; Baraghithy S
Eur J Intern Med; 2018 Mar; 49():23-29. PubMed ID: 29336868
[TBL] [Abstract][Full Text] [Related]
15. Impaired hypothalamic regulation of endocrine function and delayed counterregulatory response to hypoglycemia in Magel2-null mice.
Tennese AA; Wevrick R
Endocrinology; 2011 Mar; 152(3):967-78. PubMed ID: 21248145
[TBL] [Abstract][Full Text] [Related]
16. Endocannabinoid signaling in hypothalamic-pituitary-adrenocortical axis recovery following stress: effects of indirect agonists and comparison of male and female mice.
Roberts CJ; Stuhr KL; Hutz MJ; Raff H; Hillard CJ
Pharmacol Biochem Behav; 2014 Feb; 117():17-24. PubMed ID: 24316201
[TBL] [Abstract][Full Text] [Related]
17. A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice.
Han JH; Shin H; Park JY; Rho JG; Son DH; Kim KW; Seong JK; Yoon SH; Kim W
FASEB J; 2019 Mar; 33(3):4314-4326. PubMed ID: 30566396
[TBL] [Abstract][Full Text] [Related]
18. Loss of Magel2 impairs the development of hypothalamic Anorexigenic circuits.
Maillard J; Park S; Croizier S; Vanacker C; Cook JH; Prevot V; Tauber M; Bouret SG
Hum Mol Genet; 2016 Aug; 25(15):3208-3215. PubMed ID: 27288456
[TBL] [Abstract][Full Text] [Related]
19. Magel2 is required for leptin-mediated depolarization of POMC neurons in the hypothalamic arcuate nucleus in mice.
Mercer RE; Michaelson SD; Chee MJ; Atallah TA; Wevrick R; Colmers WF
PLoS Genet; 2013; 9(1):e1003207. PubMed ID: 23341784
[TBL] [Abstract][Full Text] [Related]
20. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.
Hsiao WC; Shia KS; Wang YT; Yeh YN; Chang CP; Lin Y; Chen PH; Wu CH; Chao YS; Hung MS
Diabetes Obes Metab; 2015 May; 17(5):495-504. PubMed ID: 25656402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
